Nucleic Acids Research, Vol 25, Issue 19 3823-3831, Copyright © 1997 by Oxford University Press
R Gonsky, JA Knauf, R Elisei, JW Wang, S Su and JA Fagin
The mRNAs of transiently expressed proteins such as cytokines and proto-
oncogenes are commonly subject to rapid transcriptional activation and
degradation. Transcript turnover is determined in part by association of
certain proteins with consensus AU-rich motifs (AUUUA) in the 3'-
untranslated region of the transcripts. Here we report a modification of
differential RNA display (DRD) to detect differentially expressed rapid
turnover mRNAs containing AU-rich motifs from thyroid cancer tissues and
cell lines. RNA of normal and thyroid cancer tissues was differentially
displayed using a 3'anchor primer to the poly(A) tail and an arbitrary
5'primer incorporating an AUUUA sequence. The appropriateness of the
strategy was established by its ability to display known early response
genes, such as c- fos, using partially degenerate primers. To test whether
the novel cDNAs isolated coded for transcripts subject to rapid turnover,
they were used as probes for Northern blots of RNA from clonal human
thyroid carcinoma cell lines treated for varying periods with either
cycloheximide or actinomycin D. A number of novel differentially expressed
cDNA fragments were isolated from human papillary thyroid carcinoma
tissues, among them a cDNA with zinc finger motifs and homology to other
zinc finger proteins. Using this fragment to probe a cDNA library, a
full-length cDNA (ZnF20) was isolated that was 4333 bp in length and
contained an open reading frame of 1029 amino acids. The ZnF20 cDNA
hybridized to multiple transcripts in a thyroid cancer cell line (8.0, 4.5
and 2 kb) that increased after cycloheximide treatment and decayed <2 h
after addition of actinomycin D. The ZnF20 mRNA was overexpressed in three
of six thyroid papillary carcinomas as compared with paired normal thyroid
tissue controls. The data presented here support the use of a targeted DRD
approach for the isolation of rapid turnover mRNAs, many of which may be
interesting candidate oncogenes.
ARTICLES
Identification of rapid turnover transcripts overexpressed in thyroid tumors and thyroid cancer cell lines: use of a targeted differential RNA display method to select for mRNA subsets
Division of Endocrinology and Metabolism, University of Cincinnati School of Medicine, Cincinnati, OH 45267-0547, USA.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C. S. Mitsiades, P. Hayden, V. Kotoula, D. W. McMillin, C. McMullan, J. Negri, J. E. Delmore, V. Poulaki, and N. Mitsiades Bcl-2 Overexpression in Thyroid Carcinoma Cells Increases Sensitivity to Bcl-2 Homology 3 Domain Inhibition J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4845 - 4852. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Mitsiades, J. Negri, C. McMullan, D. W. McMillin, E. Sozopoulos, G. Fanourakis, G. Voutsinas, S. Tseleni-Balafouta, V. Poulaki, D. Batt, et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications Mol. Cancer Ther., March 1, 2007; 6(3): 1070 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Mitsiades, D. McMillin, V. Kotoula, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, S. Tseleni-Balafouta, K. B. Ain, and N. Mitsiades Antitumor Effects of the Proteasome Inhibitor Bortezomib in Medullary and Anaplastic Thyroid Carcinoma Cells in Vitro J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4013 - 4021. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Mitsiades, V. Kotoula, V. Poulaki, E. Sozopoulos, J. Negri, E. Charalambous, G. Fanourakis, G. Voutsinas, S. Tseleni-Balafouta, and N. Mitsiades Epidermal Growth Factor Receptor as a Therapeutic Target in Human Thyroid Carcinoma: Mutational and Functional Analysis J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3662 - 3666. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Mitsiades, V. Poulaki, G. Fanourakis, E. Sozopoulos, D. McMillin, Z. Wen, G. Voutsinas, S. Tseleni-Balafouta, and N. Mitsiades Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin. Cancer Res., June 15, 2006; 12(12): 3705 - 3712. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Mitsiades, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, A. Goudopoulou, V. M. Richon, P. A. Marks, and N. Mitsiades Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3958 - 3965. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Poulaki, C. S. Mitsiades, C. McMullan, D. Sykoutri, G. Fanourakis, V. Kotoula, S. Tseleni-Balafouta, D. A. Koutras, and N. Mitsiades Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5392 - 5398. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Magro, D. Perissinotto, M. Schiappacassi, S. Goletz, A. Otto, E.-C. Muller, M. Bisceglia, G. Brown, T. Ellis, S. Grasso, et al. Proteomic and Postproteomic Characterization of Keratan Sulfate-Glycanated Isoforms of Thyroglobulin and Transferrin Uniquely Elaborated by Papillary Thyroid Carcinomas Am. J. Pathol., July 1, 2003; 163(1): 183 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Poulaki, C. S. Mitsiades, V. Kotoula, S. Tseleni-Balafouta, A. Ashkenazi, D. A. Koutras, and N. Mitsiades Regulation of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Thyroid Carcinoma Cells Am. J. Pathol., August 1, 2002; 161(2): 643 - 654. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S.A. Khabar, M. Dhalla, T. Bakheet, C. Sy, and L. al-Haj An Integrated Computational and Laboratory Approach for Selective Amplification of mRNAs Containing the Adenylate Uridylate-Rich Element Consensus Sequence Genome Res., June 1, 2002; 12(6): 985 - 995. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Knauf, L. S. Ward, Y. E. Nikiforov, M. Nikiforova, E. Puxeddu, M. Medvedovic, T. Liron, D. Mochly-Rosen, and J. A. Fagin Isozyme-Specific Abnormalities of PKC in Thyroid Cancer: Evidence for Post-Transcriptional Changes in PKC Epsilon J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2150 - 2159. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mitsiades, V. Poulaki, S. Tseleni-Balafouta, D. A. Koutras, and I. Stamenkovic Thyroid Carcinoma Cells Are Resistant to FAS-mediated Apoptosis But Sensitive to Tumor Necrosis Factor-related Apoptosis-inducing Ligand Cancer Res., August 1, 2000; 60(15): 4122 - 4129. [Abstract] [Full Text] |
||||
![]() |
T. L. Sander, A. L. Haas, M. J. Peterson, and J. F. Morris Identification of a Novel SCAN Box-related Protein That Interacts with MZF1B. THE LEUCINE-RICH SCAN BOX MEDIATES HETERO- AND HOMOPROTEIN ASSOCIATIONS J. Biol. Chem., April 21, 2000; 275(17): 12857 - 12867. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Williams, S. C. Blacklow, and T. Collins The Zinc Finger-Associated SCAN Box Is a Conserved Oligomerization Domain Mol. Cell. Biol., December 1, 1999; 19(12): 8526 - 8535. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Knauf, R. Elisei, D. Mochly-Rosen, T. Liron, X.-N. Chen, R. Gonsky, J. R. Korenberg, and J. A. Fagin Involvement of Protein Kinase Cepsilon (PKCepsilon ) in Thyroid Cell Death. A TRUNCATED CHIMERIC PKCepsilon CLONED FROM A THYROID CANCER CELL LINE PROTECTS THYROID CELLS FROM APOPTOSIS J. Biol. Chem., August 13, 1999; 274(33): 23414 - 23425. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mitsiades, V. Poulaki, G. Mastorakos, S. Tseleni-Balafouta, V. Kotoula, D. A. Koutras, and M. Tsokos Fas Ligand Expression in Thyroid Carcinomas: A Potential Mechanism of Immune Evasion J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2924 - 2932. [Abstract] [Full Text] |
||||







